1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62608AFF6609CB67085257DBD0071694A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-support-excellence-program-structure-and-effectiveness
18
19
2034.237.76.91
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Patient Support Excellence: Program Structure and Effectiveness

ID: 5343


Features:

12 Info Graphics

20 Data Graphics

130+ Metrics

2 Narratives


Pages/Slides: 40


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Patient Support Excellence: Program Structure and Effectiveness"



Study Overview

In the evolving global healthcare marketplace, a patient-centric approach has become a critical part of long-term success for pharmaceutical companies. Facing declining sales from patent losses and payer pressures, the pharma sector is turning to patient support programs and activities to help drive clinical and commercial success. As pharma has moved to enhance its patient programs, the industry has wrestled with both the structure and effectiveness of its patient support programs.


Best Practices, LLC conducted this study to generate reliable industry metrics on current patient support group structure and effectiveness. In particular, the study reviews current patient support group structure & reporting relationships and patient support program reach and effectiveness. This benchmarking study will provide patient support leaders with metrics and insights they can use to assess their patient support operations.

This study has small, medium and large company segments on some questions


Key Topics

  • Patient Support in Pharma
  • Program Structure
  • Program Effectiveness

Sample Key Metrics
  • Organizational structure of your Patient Support function
  • Function that Patient Support group works and reports to
  • Geographic levels that exist for Patient Support group
  • Job title that leads Patient Support group
  • Highest job title to whom Patient Support function reports
  • Where does Patient Support leadership/HQ reside?
  • Functions represented within Patient Support group
  • Rating the overall effectiveness of Patient Support group
  • Units/departments that provide funding for Patient Support programs
  • Percentage of patients targeted who are aware of Patient Support activities versus percentage of patients engaged in activities

Sample Key Finding
  • Patient Support Structure Varies by Company Size (Large Company Segment (LCS), Midsize Company Segment (MCS), Small Company Segment (SCS)):
    Patient Support Reporting Line
    43% of LCS reports to Marketing
    33% of MCS reports to Commercial
    50% of SCS have dedicated PS group

    Patient Support Group Structure
    42% of LCS is decentralized (14% centralized)
    66% of MCS is decentralized
    66% of SCS is centralized

  • Marketing is Key Function Found within Patient Support Groups: Marketing was the only function that a majority (53%) of participants said resides within their Patient Support group. Commercial and Patient Advocacy were the second most common functions (42%).


Study Methodology

Nineteen Patient Support leaders from 19 different companies participated in this study. Participants were recruited because of their involvement in Patient Support programs.

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Medical Device; Chemical


Companies Profiled:
Sanofi; Merck; GlaxoSmithKline ; Novo Nordisk; Daiichi Sankyo; Pfizer; Boehringer Ingelheim; AstraZeneca; Astellas; Baxter Healthcare; EMD Serono; Merck Serono; Celgene; UCB Pharma; Millenium; Dr Reddy's Laboratories; Roche; LEO Pharma; Horizon Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.